Related Experiment Video

Updated: Mar 13, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ

Susannah O'Sullivan1, Mei Lin Tay2, Jian-Ming Lin2

  • 1Department of Pharmacology, University of Auckland, Auckland, New Zealand.

Plos One
|October 14, 2016
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) like imatinib and nilotinib reduce bone resorption by increasing osteoprotegerin (OPG) production. Platelet-derived growth factor receptor beta (PDGFRβ) signaling is key to this TKI effect on bone metabolism.

Area of Science:

  • Pharmacology
  • Oncology
  • Bone Biology

Background:

  • Tyrosine kinase inhibitors (TKIs), including imatinib and nilotinib, treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • TKIs have been observed to inhibit osteoclastogenesis and reduce bone resorption in vitro and in patients.
  • Increased osteoprotegerin (OPG) production is a potential mechanism for these observed effects of TKIs on bone.

Purpose of the Study:

  • To investigate the role of platelet-derived growth factor receptor beta (PDGFRβ) signaling in regulating OPG production.
  • To elucidate the mechanisms by which TKIs affect osteoclastogenesis and bone resorption.
  • To explore the impact of TKIs on RANKL signaling.

Main Methods:

  • In vitro studies examining OPG production.
  • Analysis of PDGFRβ signaling pathways.
  • Investigation of TKI effects on RANKL signaling.

Main Results:

  • PDGFRβ signaling was found to regulate OPG production in vitro.
  • TKIs were shown to affect RANKL signaling by inhibiting PDGFRβ and other receptors.
  • These findings suggest a novel mechanism for TKI-mediated effects on bone metabolism.

Conclusions:

  • PDGFRβ signaling plays a significant role in regulating OPG production.
  • TKIs impact osteoclastogenesis and bone resorption through inhibition of PDGFRβ signaling.
  • Further research is warranted to explore PDGFRβ-inhibitors' clinical effects and underlying pathways.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Osteoclast Derivation from Mouse Bone Marrow06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

25.1K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K